# Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Source: https://onco.cc/trials/nct05384587/  
OnCo record `nct05384587` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT05384587 by Novartis Pharmaceuticals, with 34 participants enrolled, started 2022-11-11 and due to reach its primary completion in 2025-08-13. Interventions recorded: asciminib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05384587
- Phase: 2
- Setting: A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT05384587: https://clinicaltrials.gov/study/NCT05384587

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05384587.json